FDA Approves New Drug Developed to Treat MRSA Infections
The U.S. Food and Drug Administration (FDA) has approved the intravenous drug Dalvance to treat bacterial skin infections, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Dalvance is the first drug labeled as a Qualified Infectious Disease Product (QIDP) to receive FDA approval.
MRSA is a life-threatening bacteria that has become resistant to antibiotics and is often found in hospitals and other health care settings. MRSA outbreaks have been known to occur at schools, day care centers, and gyms. The bacteria is generally spread by skin-to-skin contact.
According to a World Health Organization (WHO) report, antibiotic-resistant infections and injuries are considered such a threat that they could disrupt the “achievements of modern medicine.” The report indicates that if the health trends continue, it could be “a very real possibility for the 21st Century” that typical antibiotics will not be effective in fighting general infections.
The Centers for Disease Control and Prevention (CDC) statistics show that about 1 in 25 hospital patients has at least one healthcare-associated infection (HAI). The data also reported that more than half of all HIAs occurred outside of the intensive care unit. The FDA hopes that approving such a QIDP drug will spawn further development of additional drugs to fight the growing epidemic of antibiotic-resistant infections.
The choice of a lawyer is an important decision and should not be based solely on advertisements.